PureTech Health PLC

PureTech Health PLC

Health CarePharmaceuticals & Biotechnology
  • Price (GBX)274.00
  • Today's Change0.00 / 0.00%
  • Shares traded90.24k
  • 1 Year change18.61%
  • Beta1.0388
Data delayed at least 20 minutes, as of Jul 06 2020 16:35 BST.
More ▼

Profile data is unavailable for this security.

About the company

PureTech Health PLC is a clinical stage biotechnology company. The Company is engaged in discovering, developing and commercializing medicines for diseases, including intractable cancers, lymphatic and gastrointestinal diseases, central nervous system disorders, and inflammatory and immunological diseases, among others. Its segments include Internal and Affiliates. The Internal division is focused on advancing a pipeline fueled by discoveries in lymphatics and immune cell trafficking to modulate disease in a tissue-specific manner. The Affiliates segment is comprised of the programs within its Affiliates division that are consolidated operational subsidiaries that have research and development programs. Its wholly owned pipeline includes various candidates, such as LYT-100, LYT-200, LYT-210, Lymphatic Targeting Chemistry Platform, Milk Exosome Platform and Meningeal Lymphatics Platform.

  • Revenue in GBP (TTM)7.86m
  • Net income in GBP337.37m
  • Incorporated2015
  • Employees300.00
  • Location
    PureTech Health PLC501 Boylston St Ste 6102BOSTON 02116-3769United StatesUSA
  • Phone+1 (617) 482-2333
  • Fax+1 (617) 482-3337
  • Websitehttp://puretechhealth.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
PRTC:LSE since
Ariya Therapeutics IncDeal completed02 Oct 201902 Oct 2019Deal completed7.45%666.98m
Data delayed at least 20 minutes, as of Jul 06 2020 16:35 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Alliance Pharma plc135.64m25.01m396.17m219.0015.821.4414.852.920.04720.04720.25580.51790.33442.905.30619,347.106.176.427.197.6363.4660.1318.4420.542.058.290.22626.8514.7425.5236.2524.436.84-11.73
Advanced Medical Solutions Group plc102.37m18.92m516.63m747.0027.512.7021.345.050.08720.08720.47210.88980.47372.583.63137,038.808.7511.409.5712.5059.0859.5618.4820.135.48--0.051413.34-0.224210.19-15.878.0218.8717.23
Vectura Group PLC178.30m-22.10m588.29m480.00--1.4218.383.30-0.0344-0.03440.27350.68590.30953.054.48371,458.30-3.84---4.35--53.45---12.39--1.85--0.0178--11.09--74.94------
Oxford BioMedica plc64.06m-16.07m621.10m500.00--7.69--9.70-0.225-0.2250.8810.9840.544410.462.54128,120.00-13.65-12.93-18.06-17.2844.2455.40-25.08-22.251.88-1.530.0999---4.0736.30-313.05--35.82--
Indivior PLC560.76m-76.10m665.61m824.00--21.30--1.19-0.1105-0.11050.74450.04270.44921.633.49680,537.60-6.1011.73-11.1830.5882.8688.38-13.5714.991.63--0.879612.38-21.89-6.78-50.92-19.77-23.08--
Puretech Health PLC7.86m337.37m781.24m300.002.301.462.6299.441.191.190.02731.880.0142--5.9326,187.6352.944.2166.316.05----3,732.69163.04----0.0570.00-52.7334.571,064.73--97.24--
Clinigen Group PLC491.70m14.10m1.09bn130.0078.742.4616.682.210.10380.10383.683.320.51017.234.253,782,308.001.462.141.752.9642.7936.022.873.340.86476.890.45154.5319.8629.26-81.02-20.34-2.9016.67
Data as of Jul 06 2020. Currency figures normalised to PureTech Health PLC's reporting currency: UK Pound GBX

Institutional shareholders

55.62%Per cent of shares held by top holders
HolderShares% Held
Invesco Asset Management Ltd.as of 31 Dec 201890.11m31.56%
Baillie Gifford & Co.as of 31 Dec 201825.42m8.91%
Jupiter Asset Management Ltd.as of 31 Dec 201818.36m6.43%
Canaccord Genuity Wealth Ltd.as of 01 Jun 20205.65m1.98%
M&G Investment Management Ltd.as of 01 Jun 20205.17m1.81%
Ruffer LLPas of 01 Jun 20204.65m1.63%
Bessemer Investment Management LLCas of 31 Jan 20202.71m0.95%
DNCA Finance SAas of 31 Dec 20192.30m0.81%
Legal & General Investment Management Ltd.as of 01 Jun 20202.22m0.78%
Majedie Asset Management Ltd.as of 30 Apr 20202.21m0.77%
More ▼
Data from 31 Dec 2019 - 31 Mar 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.